Cargando…

Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever

Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bact...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartley, M. Gill, Norville, Isobel H., Richards, Mark I., Barnes, Kay B., Bewley, Kevin R., Vipond, Julia, Rayner, Emma, Vente, Andreas, Armstrong, Stuart J., Harding, Sarah V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670379/
https://www.ncbi.nlm.nih.gov/pubmed/34917048
http://dx.doi.org/10.3389/fmicb.2021.760698
_version_ 1784614969226035200
author Hartley, M. Gill
Norville, Isobel H.
Richards, Mark I.
Barnes, Kay B.
Bewley, Kevin R.
Vipond, Julia
Rayner, Emma
Vente, Andreas
Armstrong, Stuart J.
Harding, Sarah V.
author_facet Hartley, M. Gill
Norville, Isobel H.
Richards, Mark I.
Barnes, Kay B.
Bewley, Kevin R.
Vipond, Julia
Rayner, Emma
Vente, Andreas
Armstrong, Stuart J.
Harding, Sarah V.
author_sort Hartley, M. Gill
collection PubMed
description Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bacterium which resides and replicates in acidic intracellular parasitic vacuoles. The efficacy of finafloxacin was evaluated in vivo using the A/J mouse model of inhalational Q fever and was compared to doxycycline, the standard treatment for this infection and ciprofloxacin, a comparator fluoroquinolone. Finafloxacin reduced the severity of the clinical signs of infection and weight loss associated with Q fever, but did not reduce the level of bacterial colonization in tissues compared to doxycycline or ciprofloxacin. However, histopathological analysis suggested that treatment with finafloxacin reduced tissue damage associated with C. burnetii infection. In addition, we report for the first time, the use of viable counts on axenic media to evaluate antibiotic efficacy in vivo.
format Online
Article
Text
id pubmed-8670379
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86703792021-12-15 Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever Hartley, M. Gill Norville, Isobel H. Richards, Mark I. Barnes, Kay B. Bewley, Kevin R. Vipond, Julia Rayner, Emma Vente, Andreas Armstrong, Stuart J. Harding, Sarah V. Front Microbiol Microbiology Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bacterium which resides and replicates in acidic intracellular parasitic vacuoles. The efficacy of finafloxacin was evaluated in vivo using the A/J mouse model of inhalational Q fever and was compared to doxycycline, the standard treatment for this infection and ciprofloxacin, a comparator fluoroquinolone. Finafloxacin reduced the severity of the clinical signs of infection and weight loss associated with Q fever, but did not reduce the level of bacterial colonization in tissues compared to doxycycline or ciprofloxacin. However, histopathological analysis suggested that treatment with finafloxacin reduced tissue damage associated with C. burnetii infection. In addition, we report for the first time, the use of viable counts on axenic media to evaluate antibiotic efficacy in vivo. Frontiers Media S.A. 2021-11-30 /pmc/articles/PMC8670379/ /pubmed/34917048 http://dx.doi.org/10.3389/fmicb.2021.760698 Text en Crown copyright © 2021 Dstl. Authors: Gill, Norville, Richards, Barnes, Bewley, Vipond, Rayner, Vente, Armstrong and Harding. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Hartley, M. Gill
Norville, Isobel H.
Richards, Mark I.
Barnes, Kay B.
Bewley, Kevin R.
Vipond, Julia
Rayner, Emma
Vente, Andreas
Armstrong, Stuart J.
Harding, Sarah V.
Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_full Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_fullStr Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_full_unstemmed Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_short Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
title_sort finafloxacin, a novel fluoroquinolone, reduces the clinical signs of infection and pathology in a mouse model of q fever
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670379/
https://www.ncbi.nlm.nih.gov/pubmed/34917048
http://dx.doi.org/10.3389/fmicb.2021.760698
work_keys_str_mv AT hartleymgill finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT norvilleisobelh finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT richardsmarki finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT barneskayb finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT bewleykevinr finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT vipondjulia finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT rayneremma finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT venteandreas finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT armstrongstuartj finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever
AT hardingsarahv finafloxacinanovelfluoroquinolonereducestheclinicalsignsofinfectionandpathologyinamousemodelofqfever